Ad is loading...
JSVZX
Price
$26.98
Change
-$0.28 (-1.03%)
Updated
Nov 15 closing price
VISVX
Price
$49.63
Change
-$0.34 (-0.68%)
Updated
Nov 15 closing price
Ad is loading...

JSVZX vs VISVX

Header iconJSVZX vs VISVX Comparison
Open Charts JSVZX vs VISVXBanner chart's image
JPMorgan Small Cap Value R2
Price$26.98
Change-$0.28 (-1.03%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$49.63
Change-$0.34 (-0.68%)
VolumeN/A
CapitalizationN/A
JSVZX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JSVZX vs. VISVX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JSVZX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. JSVZX (1.37B). VISVX pays higher dividends than JSVZX: VISVX (1.90) vs JSVZX (1.07). JSVZX was incepted earlier than VISVX: JSVZX (16 years) vs VISVX (27 years). JSVZX is a more actively managed with annual turnover of: 79.00 vs. VISVX (16.00). JSVZX has a lower initial minimum investment than VISVX: JSVZX (0) vs VISVX (3000). VISVX (28.71) and JSVZX (27.68) have marching annual gain over last year. VISVX return over 5 years is better than : 57.32 vs. JSVZX (14.38).
JSVZXVISVXJSVZX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years27 years-
Gain YTD13.43715.43387%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.37B57.6B2%
Annual Yield % from dividends1.071.9056%
Returns for 1 year27.6828.7196%
Returns for 3 years-18.4113.23-139%
Returns for 5 years14.3857.3225%
Returns for 10 years4.59108.214%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DX12.420.04
+0.32%
Dynex Capital
PNR105.920.06
+0.06%
Pentair plc
TGNA17.64-0.47
-2.60%
TEGNA
HCTI1.16-0.04
-3.33%
Healthcare Triangle
ATOS1.28-0.09
-6.57%
Atossa Therapeutics